Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: State-of-the-Art Review

• Published in: JACC CardioOncology 2023-04, Vol.5 (2), p.159-173
• Main Authors: Parashar, Susmita, Akhter, Nausheen, Paplomata, Elisavet, Elgendy, Islam Y., Upadhyaya, Deepa, Scherrer-Crosbie, Marielle, Okwuosa, Tochukwu M., Sanghani, Rupa M., Chalas, Eva, Lindley, Kathryn J., Dent, Susan
• Format: Article
• Language: English
• Subjects: State-of-the-Art Review
• ISSN: 2666-0873
• DOI: 10.1016/j.jaccao.2023.02.002

Improvements in early detection and treatment of gynecologic malignancies have led to an increasing number of survivors who are at risk of long-term cardiac complications from cancer treatment. Multimodality therapies for gynecologic malignancies, including conventional chemotherapy, targeted therapeutics, and hormonal agents, place patients at risk of cancer therapy-related cardiovascular toxicity during and following treatment. Although the cardiotoxicity associated with some female predominant cancers (eg, breast cancer) have been well recognized, there has been less recognition of the potential adverse cardiovascular effects of anticancer therapies used to treat gynecologic malignancies. In this review, the authors provide a comprehensive overview of the cancer therapeutic agents used in gynecologic malignancies, associated cardiovascular toxicities, risk factors for cardiotoxicity, cardiac imaging, and prevention strategies. • Cancer therapy is associated with CV toxicities in gynecologic cancers • Risk stratification at baseline and management of CV risk factors/disease is key • Prospective studies are needed on CV impact of cancer therapies in these patients